ALK rearrangement in non-small cell lung cancer

被引：0

作者：

Naulleau, Gaspard ^{[1
]}

Birsen, Gary ^{[1
]}

Mansuet-Lupo, Audrey ^{[2
,3
]}

Leroy, Karen ^{[4
]}

Wislez, Marie ^{[1
,3
]}

机构：

[1] Univ Paris Cite, Hop Cochin, AP HP Ctr, Serv Pneumol, Paris, France

[2] Univ Paris Cite, Hop Cochin, AP HP Ctr, Serv Anat Pathol, Paris, France

[3] Univ Paris Cite, Ctr Rech Cordeliers, Equipe Inflammat Complement & Canc, INSERM,U1138, Paris, France

[4] Univ Paris Cite, Hop Europeen Georges Pompidou, AP HP Ctr, Serv Biochim, Paris, France

来源：

BULLETIN DU CANCER | 2025年 / 112卷 / 03期

关键词：

ALK rearrangement; Targeted therapy; Non-small cell lung carcinoma; Resistance mechanisms; GENERATION SEQUENCING REVEALS; RECEPTOR TYROSINE KINASE; EML4-ALK FUSION GENE; HISTOLOGICAL TRANSFORMATION; NSCLC PATIENTS; RESISTANCE; ADENOCARCINOMA; CRIZOTINIB; MUTATION; ALECTINIB;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The discovery of ALK gene rearrangement in 3 to 5% of non-small cell lung carcinomas has revolutionized our understanding and therapeutic approach of these cancers. This oncogenic driver is associated with specific clinical and biological features is associated with specific clinical and biological features, mainly affecting young and never-smoker patients, with a particular tropism outcomes, with remarkable efficacy of latest-generation molecules, particularly in controlling brain metastases. However, the emergence of complex resistance mechanisms, whether ALK-dependent or ALK-independent, remains a major challenge. The comprehensive understanding of these resistance mechanisms now guides the development of next-generation inhibitors and innovative therapeutic strategies, paving the way for increasingly personalized precision medicine.

引用

页码：3S86 / 3S94

页数：9

共 68 条

[51]

Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]

[52] Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Spigel, David R. ;

Faivre-Finn, Corinne ;

Gray, Jhanelle E. ;

Vicente, David ;

Planchard, David ;

Paz-Ares, Luis ;

Vansteenkiste, Johan F. ;

Garassino, Marina C. ;

Hui, Rina ;

Quantin, Xavier ;

Rimner, Andreas ;

Wu, Yi-Long ;

Ozguroglu, Mustafa ;

Lee, Ki H. ;

Kato, Terufumi ;

de Wit, Maike ;

Kurata, Takayasu ;

Reck, Martin ;

Cho, Byoung C. ;

Senan, Suresh ;

Naidoo, Jarushka ;

Mann, Helen ;

Newton, Michael ;

Thiyagarajah, Piruntha ;

Antonia, Scott J. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (12) :1301-+

[53] Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370) [J].

Spigel, David R. ;

Reynolds, Craig ;

Waterhouse, David ;

Garon, Edward B. ;

Chandler, Jason ;

Babu, Sunil ;

Thurmes, Paul ;

Spira, Alexander ;

Jotte, Robert ;

Zhu, Jin ;

Lin, Wen Hong ;

Blumenschein, George, Jr. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (05) :682-688

[54] Overcoming resistance by ALK compound mutation (I1171S+G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer [J].

Takahashi, Ken ;

Seto, Yosuke ;

Okada, Koutaroh ;

Uematsu, Shinya ;

Uchibori, Ken ;

Tsukahara, Mika ;

Oh-hara, Tomoko ;

Fujita, Naoya ;

Yanagitani, Noriko ;

Nishio, Makoto ;

Okubo, Kenichi ;

Katayama, Ryohei .

THORACIC CANCER, 2020, 11 (03) :581-587

[55] Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib [J].

Takegawa, N. ;

Hayashi, H. ;

Iizuka, N. ;

Takahama, T. ;

Ueda, H. ;

Tanaka, K. ;

Takeda, M. ;

Nakagawa, K. .

ANNALS OF ONCOLOGY, 2016, 27 (05) :953-955

[56] Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant [J].

To, Ka-Fai ;

Tong, Joanna H. M. ;

Yeung, King S. F. ;

Lung, Raymond W. M. ;

Law, Peggy P. Y. ;

Chau, Shuk Ling ;

Kang, Wei ;

Tong, Carol Y. K. ;

Chow, Chit ;

Chan, Anthony W. H. ;

Leung, Linda K. S. ;

Mok, Tony S. K. .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (07) :883-891

[57] Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial [J].

West, Howard ;

McCleod, Michael ;

Hussein, Maen ;

Morabito, Alessandro ;

Rittmeyer, Achim ;

Conter, Henry J. ;

Kopp, Hans-Georg ;

Daniel, Davey ;

McCune, Steven ;

Mekhail, Tarek ;

Zer, Alona ;

Reinmuth, Niels ;

Sadiq, Ahad ;

Sandler, Alan ;

Lin, Wei ;

Lohmann, Tania Ochi ;

Archer, Venice ;

Wang, Lijia ;

Kowanetz, Marcin ;

Cappuzzo, Federico .

LANCET ONCOLOGY, 2019, 20 (07) :924-937

[58] The EML4-ALK Fusion Gene Is Involved in Various Histologic Types of Lung Cancers From Nonsmokers With Wild-type EGFR and KRAS [J].

Wong, Daisy Wing-Sze ;

Leung, Elaine Lai-Han ;

Kam-Ting, Kimpton ;

Tam, Issan Yee-San ;

Sihoe, Alan Dart-Loon ;

Cheng, Lik-Cheung ;

Ho, Kwok-Keung ;

Au, Joseph Siu-Kie ;

Chung, Lap-Ping ;

Wong, Maria Pik .

CANCER, 2009, 115 (08) :1723-1733

[59] Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer [J].

Wu, Yi-Long ;

Dziadziuszko, Rafal ;

Ahn, Jin Seok ;

Barlesi, Fabrice ;

Nishio, Makoto ;

Lee, Dae Ho ;

Lee, Jong-Seok ;

Zhong, Wenzhao ;

Horinouchi, Hidehito ;

Mao, Weimin ;

Hochmair, Maximilian ;

de Marinis, Filippo ;

Migliorino, M. Rita ;

Bondarenko, Igor ;

Lu, Shun ;

Wang, Qun ;

Ochi Lohmann, Tania ;

Xu, Tingting ;

Cardona, Andres ;

Ruf, Thorsten ;

Noe, Johannes ;

Solomon, Benjamin J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14) :1265-1276

[60]

Xia G, 2022, J THORAC ONCOL, V17, pS526, DOI 10.1016/j.jtho.2022.07.938

← 1 2 3 4 5 6 7 →